

MEET THE GUEST EDITOR

Guido J.R. Zaman

N.V. Organon
(a Part of Schering-Plough Corporation)
P.O. Box 20
5340 BH
Oss
The Netherlands
E-mail: guido.zaman@organon.com

Guido J.R. Zaman is Senior Director GPCR & Kinases in the Molecular Pharmacology Unit of N.V. Organon, a part of Schering-Plough Corporation (Oss, The Netherlands). He received his Ph.D. from the University of Nijmegen in 1991 and worked for five years at the Netherlands Cancer Institute in Amsterdam, before he joined Organon in 1996. Guido Zaman is a member of the Editorial Board of *Assay & Drug Discovery Technologies* and served as a guest editor of a mini-hot topic on GPCR screening of *Combinatorial Chemistry & High Throughput Screening* in 2005 (Vol. 8, No. 4).

SELECTED PUBLICATIONS

- [1] Verkaar, F.; van Rosmalen, J.W.G.; Blomenröhr, M.; van Koppen, C.J.; Blankesteijn, W.M.; Smits, J.F.M.; **Zaman, G.J.R.** G protein-independent cell-based assays for drug discovery on seven-transmembrane receptors. *Biotechnol. Ann. Rev.*, **2008**, *14*, 253-272.
- [2] van Koppen, C.J.; **Zaman, G.J.R.**; Timmers, C.M.; Kelder, J.; Mosselman, S.; van de Lagemaat, R.; Hanssen, R.G.J.M. A signaling selective, nanomolar potent allosteric low molecular weight agonist for the human luteinizing hormone receptor. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **2008**, *in press*.
- [3] Verzijl, D.; Storelli, S.; Scholten, D.; Bosch, L.; Reinhart, T.A.; Streblow, D.N.; Tensen, C.P.; Fitzsimons, C.P.; **Zaman, G.J.R.**; Pease, J.E.; de Esch, I.J.P.; Smit, M.J.; Leurs, R. Non-competitive antagonism and inverse agonism as mechanism of action of non-peptidergic antagonists at primate and rodent CXCR3 chemokine receptors. *J. Pharmacol. Exp. Ther.*, **2008**, *325*, 544-555.
- [4] Ottink, O.M.; Rampersad, S.M.; Tessari, M.; **Zaman, G.J.R.**; Heus, H.A.; Wijmenga, S.S. Ligand induced folding of the guanine sensing riboswitch is controlled by a combined predetermined-induced fit mechanism. *RNA*, **2007**, *13*, 2202-2212.
- [5] **Zaman, G.J.R.**; de Roos, J.A.D.M.; Blomenröhr, M.; van Koppen, C.J.; Oosterom, J. Cryopreserved cells facilitate cell-based drug discovery. *Drug Discov. Today*, **2007**, *12*, 521-526.
- [6] **Zaman, G.J.R.**; van der Lee, M.M.C.; Kok, J.J.; Nelissen, R.L.H.; Loomans, E.E.M.G. Enzyme fragment complementation binding assay for p38 α mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors. *Assay Drug Devel. Technol.*, **2006**, *4*, 411-420.
- [7] Oosterom, J.; van Doornmalen, E.J.P.; Lobregt, S.; Blomenröhr, M.; **Zaman, G.J.R.** High-throughput screening using β -lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor. *Assay Drug Devel. Technol.*, **2005**, *3*, 143-154.
- [8] **Zaman, G.J.R.**; Michiels, P.J.A.; van Boeckel, C.A.A. Targeting RNA: new opportunities to address drugless targets. *Drug Discov. Today*, **2003**, *8*, 297-306.
- [9] **Zaman, G.J.R.**; Garritsen, A.; de Boer, Th.; van Boeckel, C.A.A. Fluorescence assays for high-throughput screening of protein kinases. *Comb. Chem. High Throughput Screen.*, **2003**, *6*, 313-320.
- [10] Loomans, E.E.M.G.; van Doornmalen, A.M.; Wat, W.Y.; **Zaman, G.J.R.** High-Throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases. *Assay Drug Devel. Technol.*, **2003**, *1*, 445-453.